StockIceMan's Weekly Stock Pick
Week of
January 8, 2007
| Stock: |
Panacos Pharmaceuticals Inc |
|
|
| Ticker Symbol: |
PANC - Nasdaq -
Biotechnology |
|
|
| Buy: |
3.75 to 4.00 |
|
|
| Sell: |
7.00 |
|
|
|
Info: |
Panacos Pharmaceuticals,
Inc., a development stage biotechnology company,
engages in the discovery and development of
small molecule oral drugs to treat human
immunodeficiency virus (HIV) and other major
human viral diseases. Its principal product,
PA-457, under phase II clinical trials, is a new
class of oral HIV therapeutic, called maturation
inhibitor. By targeting a novel step in the
virus life cycle, maturation inhibitors are
designed to have potent activity against a range
of HIV, including strains that are resistant to
existing classes of drugs. The company’s
discovery technologies focus on novel targets in
the virus life cycle, including virus maturation
and virus fusion. It also has a research and
development program focused on an early step in
the HIV virus life cycle, fusion of the HIV
virus to human cells. Panacos Pharmaceuticals
was founded in 1999 and is based in Watertown,
Massachusetts |
|
|
| Financial Info: |
For the thirty nine weeks
ended 9/30/2006, revenues decreased 71% to
$259,000. Net loss applicable to Common
decreased 42% to $29.4 million. |
|
|
| Key Ratios: |
Current
Ratio: 13.771, Total Debt/Equity: N/A, Trailing
P/E: N/A, Forward P/E: N/A, Price/Book:
3.09, Price/Sales: 472.71 |
|
|
| Share Info: |
There are 50.72
million shares outstanding with 45.86
million shares in the trading
float. Institutions own
approximately 73.40% of the shares outstanding.
There have been 1 insider purchase totaling
25,000 shares and no insider sales in the last six months.
Real-Time SEC
Filings
As of 12/12/2006, there were 5.19 million shares short.
Net Institutional Buying: 7.167
million shares prior to latest
quarter. |
|
|
| Articles: |
Coverage initiated on
Panacos Pharma by CIBC World Markets |
|
